Lotus Pharmaceuticals, Inc. (LTUS)
OTCMKTS
· Delayed Price · Currency is USD
0.0060
0.00 (0.00%)
At close: Apr 25, 2025
Lotus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | 2005 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '11 Sep 30, 2011 | Dec '10 Dec 31, 2010 | Dec '09 Dec 31, 2009 | Dec '08 Dec 31, 2008 | Dec '07 Dec 31, 2007 | Dec '06 Dec 31, 2006 | 2005 |
| Operating Revenue | 71.39 | 72.7 | 56.48 | 68.1 | 45.12 | 28.96 | Upgrade
|
| Other Revenue | - | - | - | 5.7 | 11.75 | 7.24 | Upgrade
|
| Revenue | 71.39 | 72.7 | 56.48 | 73.8 | 56.87 | 36.21 | Upgrade
|
| Revenue Growth (YoY) | 4.26% | 28.71% | -23.47% | 29.77% | 57.07% | 97.36% | Upgrade
|
| Cost of Revenue | 45.94 | 32.92 | 25.05 | 40.65 | 33.68 | 26.13 | Upgrade
|
| Gross Profit | 25.45 | 39.78 | 31.43 | 33.15 | 23.19 | 10.08 | Upgrade
|
| Selling, General & Admin | 15.33 | 18.41 | 11.73 | 16.88 | 9.47 | 5.22 | Upgrade
|
| Research & Development | 1.95 | 0.09 | - | 1.2 | 2.41 | 0.39 | Upgrade
|
| Operating Expenses | 17.28 | 18.5 | 11.73 | 18.08 | 11.89 | 5.61 | Upgrade
|
| Operating Income | 8.17 | 21.29 | 19.7 | 15.07 | 11.31 | 4.47 | Upgrade
|
| Interest Expense | -0.25 | -0.66 | -2.57 | -2.29 | -2.24 | -0.33 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0.05 | 0.01 | 0.1 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.33 | 0.78 | 1.34 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 8.25 | 21.41 | 18.52 | 12.79 | 9.17 | 4.14 | Upgrade
|
| Asset Writedown | -6.76 | -6.76 | -1.72 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0 | 2.05 | - | Upgrade
|
| Pretax Income | 1.49 | 14.65 | 16.8 | 12.79 | 11.22 | 4.14 | Upgrade
|
| Income Tax Expense | -0.25 | 0.22 | 0.37 | - | - | - | Upgrade
|
| Net Income | 1.74 | 14.42 | 16.43 | 12.79 | 11.22 | 4.14 | Upgrade
|
| Net Income to Common | 1.72 | 14.42 | 16.43 | 12.79 | 11.22 | 4.14 | Upgrade
|
| Net Income Growth | -91.59% | -12.22% | 28.47% | 14.03% | 170.75% | 126.18% | Upgrade
|
| Shares Outstanding (Basic) | 27 | 26 | 22 | 21 | 21 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 27 | 25 | 24 | 22 | 20 | Upgrade
|
| Shares Change (YoY) | 4.11% | 7.89% | 4.14% | 9.56% | 8.67% | 0.80% | Upgrade
|
| EPS (Basic) | 0.06 | 0.55 | 0.74 | 0.60 | 0.54 | 0.21 | Upgrade
|
| EPS (Diluted) | 0.06 | 0.54 | 0.66 | 0.54 | 0.52 | 0.20 | Upgrade
|
| EPS Growth | -91.95% | -18.91% | 22.22% | 3.85% | 160.00% | 118.60% | Upgrade
|
| Free Cash Flow | -0.8 | -2.67 | 20.24 | 35.96 | -1.23 | 4.83 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.10 | 0.81 | 1.50 | -0.06 | 0.24 | Upgrade
|
| Gross Margin | 35.64% | 54.72% | 55.65% | 44.92% | 40.78% | 27.83% | Upgrade
|
| Operating Margin | 11.44% | 29.28% | 34.87% | 20.42% | 19.88% | 12.34% | Upgrade
|
| Profit Margin | 2.41% | 19.84% | 29.09% | 17.33% | 19.72% | 11.44% | Upgrade
|
| Free Cash Flow Margin | -1.13% | -3.68% | 35.84% | 48.72% | -2.17% | 13.35% | Upgrade
|
| EBITDA | 10.31 | 23.53 | 21.68 | 15.7 | 11.87 | 5.05 | Upgrade
|
| EBITDA Margin | 14.44% | 32.37% | 38.39% | 21.28% | 20.88% | 13.95% | Upgrade
|
| D&A For EBITDA | 2.14 | 2.25 | 1.99 | 0.63 | 0.56 | 0.58 | Upgrade
|
| EBIT | 8.17 | 21.29 | 19.7 | 15.07 | 11.31 | 4.47 | Upgrade
|
| EBIT Margin | 11.44% | 29.28% | 34.87% | 20.42% | 19.88% | 12.34% | Upgrade
|
| Effective Tax Rate | - | 1.50% | 2.19% | - | - | - | Upgrade
|
| Revenue as Reported | 71.39 | 72.7 | 56.48 | 73.8 | 56.87 | 36.21 | Upgrade
|
| Advertising Expenses | - | - | 0.05 | 0.18 | 2.6 | 0.08 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.